Great Lakes Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $443K | Sell |
3,521
-28,485
| -89% | -$3.58M | ﹤0.01% | 634 |
|
|
2025
Q1 | $3.54M | Buy |
32,006
+27,431
| +600% | +$3.03M | 0.03% | 340 |
|
|
2024
Q4 | $624K | Sell |
4,575
-5,832
| -56% | -$796K | 0.01% | 629 |
|
|
2024
Q3 | $1.2M | Sell |
10,407
-100,871
| -91% | -$11.6M | 0.01% | 561 |
|
|
2024
Q2 | $15.3M | Sell |
111,278
-4,339
| -4% | -$597K | 0.14% | 149 |
|
|
2024
Q1 | $15.9M | Sell |
115,617
-47,868
| -29% | -$6.6M | 0.14% | 154 |
|
|
2023
Q4 | $21.5M | Buy |
163,485
+1,528
| +0.9% | +$201K | 0.21% | 122 |
|
|
2023
Q3 | $18.2M | Buy |
161,957
+121,592
| +301% | +$13.7M | 0.17% | 129 |
|
|
2023
Q2 | $3.81M | Sell |
40,365
-43,349
| -52% | -$4.09M | 0.04% | 380 |
|
|
2023
Q1 | $8.47M | Buy |
83,714
+41,488
| +98% | +$4.2M | 0.08% | 248 |
|
|
2022
Q4 | $5.04M | Sell |
42,226
-878
| -2% | -$105K | 0.29% | 124 |
|
|
2022
Q3 | $4.58M | Buy |
+43,104
| New | +$4.58M | 0.1% | 225 |
|
|
2018
Q4 | – | Sell |
-75,389
| Closed | -$9.27M | – | 606 |
|
|
2018
Q3 | $9.27M | Buy |
+75,389
| New | +$9.27M | 0.2% | 113 |
|